Powell Andrew Kenneth William 4
4 · Aclaris Therapeutics, Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
Powell Andrew Kenneth William
Director
Transactions
- Purchase
Common Stock
2024-03-01$1.23/sh+8,500$10,455→ 22,863 total - Purchase
Common Stock
2024-03-04$1.25/sh+6,000$7,500→ 28,863 total
Footnotes (2)
- [F1]The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.2393, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.269, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.